TEM logo

TEM Tempus AI Inc

$72.43
$11.57
(13.85%)
Today
Closed $71.98
$0.45
(0.63%)
After Hours
71

Bullish Sentiment

How do you feel about TEM?

Loading...
Here's How Tempus AI is Capitalizing on AI-ECG Market Growth
TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.
Zacks
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...
PR Newswire
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 2327 in Madrid. At this years congress, Tempus will showcase clinical research revealing insights in cancer...
Business Wire
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral...
Business Wire
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Key PointsThe transaction involved 7,062 shares with an estimated value of $529,650 as of the transaction date...
Nasdaq News: Markets
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
Zacks
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursions RNA Foundation Model
Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursions RNA Foundation Model. Tempus and Recursion have...
Business Wire
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Zacks Investment Ideas feature highlights: NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver
NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver have been highlighted in this Investment Ideas article.
Zacks